-
2024-520014-22-00
5
2026-04-22
Locally advanced/metastatic urothelial carcinoma
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2025-522583-32-00
5
2026-04-13
Cold-Induced Urticaria and Symptomatic Dermographism
-
2025-523085-24-00
5
2026-04-13
Biliary Tract Cancer
-
2025-523263-37-00
10
2026-04-08
Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal
-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2025-521973-16-00
9
2026-03-31
Netherton Syndrome
-
2024-516544-26-00
4
2026-03-30
acute ischemic stroke
-
2025-522544-40-00
5
2026-03-27
Hereditary transthyretin-mediated amyloidosis with polyneuropathy
-
2023-504957-11-00
5
2026-03-24
Metastatic castration resistant prostate cancer
-
2025-522674-36-00
5
2026-03-24
Metabolic Dysfunction-Associated Steatotic Liver Disease
-
2025-523141-10-00
4
2026-03-20
Active Psoriatic Arthritis
-
2024-519344-32-00
9
2026-03-16
Non-small Cell Lung Cancer
-
2025-521621-33-00
6
2026-03-16
Metastatic Melanoma
-
2025-522232-13-00
4
2026-03-06
Sepsis-associated acute kidney injury (AKI)
-
2025-521284-12-00
5
2026-03-05
Non-small cell lung cancer
-
2025-520790-39-00
3
2026-03-04
relapsed or refractory AL amyloidosis
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2025-521124-29-00
10
2026-02-13
Non-Small Cell Lung Cancer
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-521627-78-00
5
2026-01-28
Neoplasms, Lung
-
2025-521768-36-00
9
2026-01-27
Metastatic colorectal cancer